

MOL #104927

## **Corticotropin-releasing factor receptors and their interacting proteins: functional consequences**

**Paula G. Slater, Hector E. Yarur, Katia Gysling**

Dept of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile

MOL #104927

**Running title:** CRF receptor's interacting proteins

**Correspondence to:**

Dr. Katia Gysling

Alameda 340, Santiago, 8331150

CHILE

Email: [kgysling@bio.puc.cl](mailto:kgysling@bio.puc.cl)

Number of pages: 29

Number of figures: 1

Number of references: 74

Number of words in Abstract: 76

Number of words in text (excluding references): 4021

**Abbreviations:** 5-HT, 5-hydroxytryptamine; 5-HT<sub>2</sub>R, 5-HT<sub>2</sub> receptors; ACTH, adrenocorticotrophic hormone; BRET, bioluminescence resonance energy transfer; Co-IP, co-immunoprecipitation; CRF, corticotropin-releasing factor; CRF-BP, CRF binding protein, CRF<sub>1</sub>R, type-1 CRF receptor; CRF<sub>2</sub>R, CRF type-2 receptor; CRF<sub>2α</sub>R, type-2 alpha CRF receptor; CRF<sub>2β</sub>R, type-2 beta CRF receptor; CRF<sub>2γ</sub>R, type-2 gamma CRF receptor; D<sub>1</sub>R, dopamine type-1 receptor; ER, endoplasmic reticulum; FRET, fluorescence resonance energy transfer; GRKs, GPCR kinases; GPCRs, G-protein coupled receptors; HTRF, homogeneous time resolved fluorescence; MAGUKs, membrane-associated guanylate kinases; OX<sub>1</sub>R, orexin 1 receptor; OX-A, Orexin-A; PFC, prefrontal cortex; PDZ, PSD95/discs large/occludens zone 1; class I PDZ binding domain (STAV); RAMP2, receptor activity-modifying protein 2; σ<sub>1</sub>R, sigma 1 receptor, AVP, vasopressin; V<sub>1b</sub>R, AVP 1b receptor; VTA, ventral tegmental area.

MOL #104927

## **ABSTRACT**

The corticotropin-releasing factor (CRF) system, which is involved in stress, addiction, and anxiety disorders such as depression, acts through G-protein coupled receptors (GPCRs) known as type-1 and type-2 CRF receptors. The purpose of this review is to highlight recent advances on the interactions of CRF receptors with other GPCRs and non-GPCR proteins and their associated functional consequences. A better understanding of these interactions may generate new pharmacological alternatives for the treatment of addiction and stress-related disorders.

MOL #104927

## INTRODUCTION

Compelling evidence exists that indicates that G-protein coupled receptors (GPCRs) exist as dimers/oligomers that are formed by identical receptor molecules (homomers) or by different receptor molecules (heteromers) as opposed to monomers (Franco et al., 2008). The criteria to consider a protein-protein interaction between receptors as a heteromer has been described by Pin et al (2007), and the available evidence shows that the assembly between GPCRs is fundamental for many functional aspects of GPCRs; the multimers usually exhibit different properties than the protomers (Szafran et al., 2013; Terrillon and Bouvier, 2004). The following situations have been associated with the homo and heteromerization of GPCRs: 1) the interaction between GPCRs is fundamental for the correct functioning of some receptors; 2) The homo or heteromerization can be constitutive or regulated by a ligand; 3) GPCR assembly can change the pharmacological properties of the individual receptors as demonstrated by the affinity for a ligand increasing or diminishing and the occurrence of a positive or negative cooperativity between different ligands; 4) A change in signal transduction, either potentiation, attenuation, or changes in the G-protein subfamily coupled to the receptors can occur in both homomers and heteromers; and, 5) Endocytosis of some GPCRs can be also affected; the stimulation of one protomer can be sufficient for the internalization of both receptors (Terrillon and Bouvier, 2004).

In addition to homo and heteromerization, increasing evidence shows that GPCRs may also interact with the non-GPCR proteins that regulate their trafficking to the plasma membrane and /or their function (Latchie et al., 1998; Doly and Marullo, 2015). Evidence showing

MOL #104927

that GPCRs homo and heteromerize, and that GPCR interactions with other non-GPCR proteins confers new and different receptor properties, has opened new avenues for the development of more selective pharmacological tools (Rozenfeld and Devi, 2010).

In this review, we will summarize the existing data regarding homo and heteromerization of corticotropin-releasing factor (CRF) receptors and their interaction with non-GPCR proteins.

### **Description of the corticotropin-releasing factor system**

The CRF system is comprised of four neuropeptides: CRF and urocortin 1-3, type-1 (CRF<sub>1</sub>R) and type-2 (CRF<sub>2</sub>R) CRF receptors, and CRF binding proteins (CRF-BP) (Bale and Vale, 2004; Gysling, 2012). CRF and urocortin 1 have high affinity for both types of CRF receptors, while urocortin 2 and urocortin 3 have high affinity only for CRF<sub>2</sub>R and CRF and urocortin 1 have high affinity for CRF-BP. Urocortin 2 has low affinity and urocortin 3 has no affinity for CRF-BP (Bale and Vale, 2004).

The human CRFRs are encoded by different genes, but the proteins share high sequence homology (70%). The lowest degree of homology is found in the N-terminal domain (40%) (Dautzenberg and Hauger, 2002) and many splice variants exist for both receptors. CRF<sub>1</sub>R cDNA sequence predicts a protein of 415–420 amino acids with one functional and several non-functional isoforms (Dautzenberg et al., 2001; Grammatopoulos and Chrousos, 2002), while CRF<sub>2</sub>R has three known functional isoforms. CRF<sub>2 $\alpha$</sub> R is 411 amino acids in length (Liaw et al., 1996), and the first 34 amino acids are replaced by a sequence of 61 amino acids in the case of CRF<sub>2 $\beta$</sub> R, which encodes a protein of 438 amino acids (Valdenaire et al.,

MOL #104927

1997; Grammatopoulos and Chrousos, 2002). The same 34 amino acids are changed by a sequence of 20 amino acids in the case of the 397 amino acids long CRF<sub>2 $\gamma$</sub> R protein (Kostich et al., 1998). Besides the N-terminal domain differences, the 3 CRF<sub>2</sub>R splice variants have different tissue distribution; CRF<sub>2 $\alpha$</sub> R the most abundant isoform in the brain (Dautzenberg and Hauger, 2002; Hauger et al., 2006) and CRF<sub>2 $\beta$</sub> R is found almost exclusively in peripheral organs and systems such as the cardiovascular system, intestine, uterus, liver, and placenta (Dautzenberg and Hauger, 2002).

## **Homo and heteromerization of CRF receptors**

### ***Homodimerization of CRF receptors***

CRF<sub>1</sub>R (Kraetke et al., 2005) and CRF<sub>2 $\beta$</sub> R (Milan-Lobos et al., 2009), but not CRF<sub>2 $\alpha$</sub> R (Teichmann et al., 2012), are capable of homodimerization. CRF<sub>1</sub>R was the first class B GPCR to be described as having the ability to form homomers. Using the methodology of fluorescence resonance energy transfer (FRET) in HEK293T cells, Kraetke et al. (2005) showed that CRF<sub>1</sub>R form homomers in the plasma membrane and in intracellular compartments. Interestingly, the level of CRF<sub>1</sub>R homodimerization was unaffected by the presence of different CRF<sub>1</sub>R agonists, indicating that the homomer assembly does not require a ligand. The presence of homomers in intracellular compartments indicates that their assembly may start intracellularly. As with the GABA<sub>B</sub> receptor (White et al., 1998), CRF<sub>1</sub>R homodimerization in intracellular compartments could be regulating the presence of CRF<sub>1</sub>R in the plasma membrane. It has also been shown that CRF<sub>2 $\beta$</sub> R homodimerize in HEK293 transfected cells. Milan-Lobos et al. (2009) compared the homodimerization of

MOL #104927

CRF<sub>1</sub>R and CRF<sub>2β</sub>R and observed that both receptors form homomers in the absence of ligand. Further studies should address the functional consequences of their homodimerization.

CRF<sub>1</sub>R and CRF<sub>2β</sub>R differ from CRF<sub>2α</sub>R in the structure of the N-terminal extracellular domain. The N-terminal extracellular domain of the three receptors form the same fold, but CRF<sub>2α</sub>R N-terminal contains a hydrophobic  $\alpha$ -helix formed by its non-cleavable pseudo-signal peptide, in contrast to CRF<sub>1</sub>R and CRF<sub>2β</sub>R that have a cleavable signal peptide (Rutz et al., 2006; Pal et al., 2010). The capacity of CRF<sub>1</sub>R and CRF<sub>2α</sub>R to form homomers or monomers is due to the absence or presence of the signal-peptide, respectively (Fig. 1). Utilizing chimeras and FRET analyses, Teichmann et al. (2012) elegantly showed that the pseudo-signal peptide of CRF<sub>2α</sub>R is responsible for the monomeric form of the receptor; the CRF<sub>1</sub>R chimera containing the CRF<sub>2α</sub>R non-cleavable pseudo-signal peptide prevented receptor homodimerization, and the CRF<sub>2α</sub>R chimera containing the CRF<sub>1</sub>R cleavable signal peptide was able of homodimerize.

In 2014, Teichmann et al. showed that CRF<sub>1</sub>R transfected into HEK293T cells exists in the plasma membrane as monomers and homodimers, and that the formation of higher-level oligomers was not observed. In addition, the experiments showed that 22-29 % of CRF<sub>1</sub>R present in the plasma membrane was homodimerized and that this percentage was not modified by the presence of sauvagine, a CRFR agonist.

The ability of CRF<sub>1</sub>R to exist as either a monomer or homodimer could affect its downstream signaling. Schulz et al. (2010) showed that the activation of CRF<sub>1</sub>R yields a biphasic concentration-response curve for cAMP accumulation in the cell, which is

MOL #104927

generated by the association of the receptor to a  $G_s$  protein at low agonist concentration and to a  $G_i$  protein at high agonist concentration. On the other hand,  $CRF_{2\alpha}R$  yields a monophasic concentration-response curve for cAMP cell accumulation, which is generated by the association of the receptor to only the  $G_s$  protein. These signaling characteristics were transferable when the signal peptide was exchanged and the biogenesis and the cell surface levels of the CRFRs were also affected (Rutz et al., 2006; Schulz et al., 2010). The pseudo-signal peptide, responsible for the monomeric form of  $CRF_{2\alpha}R$ , leads to an immature non-glycosylated state of the receptor and low levels of  $CRF_{2\alpha}R$  in the cell surface. In contrast, the cleavage of the signal-peptide in  $CRF_1R$  leads to high levels of the receptor in the cell surface (Fig.1).

### ***Heteromerization of $CRF_1R$***

There is evidence of heteromerization of  $CRF_1R$  with the vasopressin (AVP)  $V_{1b}$  receptor ( $V_{1b}R$ ) (Murat et al., 2012), the orexin 1 receptor ( $OX_1R$ ) (Navarro et al., 2015), and the 5-hydroxytryptamine receptor ( $5-HT_2R$ ) (Magalhaes et al., 2010). AVP and CRF release adrenocorticotrophic hormone (ACTH) from the anterior pituitary, and the receptors involved are  $V_{1b}R$  and  $CRF_1R$ , respectively (Guillon et al., 1987, Liebsch et al., 1999). Gillies et al. (1982) showed that CRF and AVP have a synergistic effect on the release of ACTH from the pituitary, and Young et al. (2007), using co-immunoprecipitation (Co-IP) and Bioluminescence Resonance Energy Transfer (BRET) techniques, showed that  $V_{1b}R$  and  $CRF_1R$  are able to interact in CHO cells. The interaction of  $V_{1b}R$  and  $CRF_1R$  is not dependent on the presence of their agonists, suggesting that their heteromerization is



MOL #104927

constitutive and not a process regulated by their ligands. The presence of agonists for  $V_{1b}R$  and  $CRF_1R$  do not modify the number of receptors that bind to their ligands in the plasma membrane. Murat et al. (2012) addressed the question of how the synergistic action of AVP and CRF takes place in the pituitary. These authors documented the heteromerization of  $V_{1b}R$  with  $CRF_1R$  using BRET, Co-IP, and receptor rescue experiments and showed that the activation of either  $V_{1b}R$  or  $CRF_1R$ , naturally expressed in bovine chromaffin cells, was able to induce catecholamine secretion. Interestingly, the co-infusion of both agonists induced a synergistic action on catecholamine secretion. Considering the evidence presented above, it is clear that the presence of the  $V_{1b}R/CRF_1R$  heteromer is crucial for the synergistic effect of AVP and CRF for releasing ACTH. The functional relevance of this heteromer may explain the observations made in knockout mice for  $V_{1b}R$  (Tanoue et al., 2004); in these mice, the circulating levels of ACTH were lower at resting conditions and under stress induced by forced swimming (Tanoue et al., 2004).

CRF plays a key role in the plastic changes associated with stress and drug abuse (Shaham et al., 1998; Ungless et al., 2003; Williams et al., 2014; Zorrilla et al., 2014; Sotomayor-Zarate et al., 2015).  $CRF_1R$  is involved in the sensitization of dopaminergic neurons by CRF in the ventral tegmental area (VTA) after cocaine administration and in stress-induced relapse to cocaine seeking (Hahn et al., 2009; Blacktop et al., 2011). The neuropeptide orexin-A (OX-A) has also been involved in relapse to cocaine seeking (Boutrel et al., 2005). Relapse was prevented by a nonselective antagonist of CRF receptors and a selective antagonist of the orexin 1 receptor ( $OX_1R$ ). Wang et al. (2009) reported that VTA CRF and

MOL #104927

OX-A were involved in stress-induced relapse to cocaine seeking by independent mechanisms.

Navarro et al. (2015) investigated whether CRF<sub>1</sub>R and OX<sub>1</sub>R were able to form heteromers in cell lines and *in vivo*, and obtained compelling evidence of the heteromerization of CRF<sub>1</sub>R and OX<sub>1</sub>R that determines a negative crosstalk between both receptors. The use of peptides bearing the sequence of transmembrane domains, TM1 and TM5 of OX<sub>1</sub>R, allowed the disassembly of the heteromer and consequently the negative cross signaling between both receptors, confirming that the integrity of the heteromer is crucial for the crosstalk between the receptors. Interestingly, the negative crosstalk between CRF<sub>1</sub>R and OX<sub>1</sub>R was also observed in VTA slices. CRF<sub>1</sub>R signals through G<sub>s</sub>-protein increasing cAMP production, while OX<sub>1</sub>R signals through G<sub>i</sub>-protein decreasing cAMP synthesis. The infusion of an antagonist for one of the receptors antagonized the cAMP effect of the agonist for the other receptor. The negative crosstalk between CRF and OX-A was perceived not only at the level of second messengers, but also at the level of dopamine release. The release of dopamine in the VTA was antagonized by infusing antagonists for CRF<sub>1</sub>R and OX<sub>1</sub>R, but was recovered by infusing the agonists for the receptors in the VTA. Therefore, the CRF<sub>1</sub>R/OX<sub>1</sub>R heteromer is present in the VTA and plays a role in controlling dopamine release. Further studies should address the apparent discrepancies between this work and the independent control exerted by CRF and OX-A previously described (Wang et al., 2009). Navarro et al. (2015) also found that the sigma 1 receptor ( $\sigma_1$ R) was able to oligomerize with the CRF<sub>1</sub>R/OX<sub>1</sub>R heteromer, specifically with CRF<sub>1</sub>R. The activation of  $\sigma_1$ R eliminates the negative crosstalk between CRF and OX-A in the

MOL #104927

VTA (Navarro et al., 2015). It is tempting to suggest that the activation of  $\sigma_1$ R may explain the apparent differences between the work of Wang et al. (2009) and that of Navarro et al. (2015). It was described that cocaine is an agonist for  $\sigma_1$ R (Kourrich et al., 2012) and this evidence suggests that the CRF<sub>1</sub>R/ $\sigma_1$ R/OX<sub>1</sub>R oligomer may be a potential target for the pharmacological treatment of addiction.

The CRF system also plays a key role in anxiety disorders, such as depression (Reul and Holsboer, 2002; Kehne, 2007). CRF and 5-HT are known to influence and modulate depressive and anxiety-like behaviors (Müller et al., 2003; Bockaert et al., 2006.), and Tan et al. (2004) demonstrated that the activation of CRF<sub>1</sub>R in neurons of the PFC results in the modulation of 5-HT<sub>2</sub>R signaling. The sIPSC in the PFC were increased by the stimulation with 5-HT in PFC slices pretreated with CRF or obtained from stressed animals, suggesting that CRF<sub>1</sub>R and 5-HT<sub>2</sub>R may be interacting in the PFC. Magalhaes et al. (2010) showed that the activation of CRF<sub>1</sub>R increased inositol phosphate formation induced by the activation of 5-HT<sub>2</sub>R in heterologous cell cultures as well as in mouse cortical neurons. The increase in inositol phosphate produced by pretreatment with CRF is not due to CRF<sub>1</sub>R activation; the stimulation CRF<sub>1</sub>R alone does not lead to the formation of inositol phosphate. Interestingly, when the cells were first pretreated with 5-HT and thereafter with a CRF<sub>1</sub>R agonist, no significant increase in cAMP production in response to the activation of CRF<sub>1</sub>R was observed. Thus, the synergistic effect between both receptors is observed only when CRF<sub>1</sub>R is stimulated before 5-HT<sub>2</sub>R. The functional consequence of the CRF<sub>1</sub>R/5-HT<sub>2</sub>R interaction is that previous exposure of the prefrontal cortex to CRF increases 5-HT<sub>2</sub> dependent behavior induced by 2,5-dimethoxy-4-iodoamphetamine

MOL #104927

(Magalhaes et al., 2010). Magalhaes et al. (2010) found that a subpopulation of neurons in the PFC express the CRF<sub>1</sub> and 5-HT<sub>2A</sub> receptors. In the presence of CRF, both receptors were endocytosed and located in intracellular vesicles. Subsequently, it was observed that the endocytosis and recycling of CRF<sub>1</sub>R was essential for the synergism between CRF<sub>1</sub>R and 5-HT<sub>2R</sub>. These authors also described that the interaction between 5-HT<sub>2R</sub> and CRF<sub>1</sub>R occurs through their PSD95/discs large/occludens zone 1 domains (PDZ)-binding domains in the carboxyl terminal domain of both receptors. This is one of the critical differences between CRF<sub>1</sub>R and CRF<sub>2</sub>R because the class I PDZ-binding domain (STAV) is only found in CRF<sub>1</sub>R (Fig. 1). Therefore, CRF<sub>1</sub>R, but not CRF<sub>2 $\alpha$</sub> R and CRF<sub>2 $\beta$</sub> R, is able to interact with 5-HT<sub>2R</sub>. Interestingly, it was proposed that this interaction is not direct and depends on a PDZ domain containing protein (Magalhaes et al, 2012). PDZ domains are usually the sites of interaction of non-GPCR proteins with GPCRs.

### ***Heteromerization of CRF<sub>2</sub>R***

At present, there is only evidence of the heteromerization of CRF<sub>2 $\alpha$</sub> R with the dopamine type-1 receptor (D<sub>1</sub>R) (Fuenzalida et al., 2014), and this heteromer assembles in the absence of ligands. The evidence was obtained in HEK293T cells co-transfected with the receptors using FRET, BRET, Co-IP and HTRF to measure cAMP accumulation in the cells. It was also observed that the CRF<sub>2 $\alpha$</sub> R/D<sub>1</sub>R heteromer had a number of different characteristics than the protomers: 1) the subcellular localization of the receptors changed. The D<sub>1</sub>R is located mainly in the cell surface (O'Dowd et al., 2005) and CRF<sub>2 $\alpha$</sub> R intracellularly (Waselus et al., 2009; Wood et al., 2013). However, when the receptors are

MOL #104927

co-expressed, the D<sub>1</sub>R is found mostly in the endoplasmic reticulum (ER) co-localizing with CRF<sub>2α</sub>R; 2) the signaling properties also changed. CRF<sub>2α</sub>R and D<sub>1</sub>R couple to G<sub>s</sub> protein, resulting in intracellular cAMP accumulation (Neve et al., 2004; Dautzenberg and Hauger, 2002) and the CRF<sub>2α</sub>R/D<sub>1</sub>R heteromer maintained the signaling through cAMP upon stimulation with CRF<sub>2α</sub>R and D<sub>1</sub>R agonists. However, the protein was also able to mobilize intracellular calcium upon stimulation with D<sub>1</sub>R agonist. Moreover, synergism was described between CRF<sub>2α</sub>R and D<sub>1</sub>R in the synaptic transmission from rat basolateral amygdala to PFC (Orozco-Cabal et al., 2008). The authors, utilizing electrophysiological approaches, showed that the activation of either of these receptors increases cocaine-induced synaptic depression. When both receptors were activated, a positive cooperativity between both ligands was observed on synaptic depression. Moreover, after chronic cocaine use, the activation of both receptors induced synaptic facilitation; these results led the authors of the study to propose the existence of heteromers between dopamine and CRF receptors (Orozco-Cabal et al., 2008).

### **CRF receptors and their interaction with non-GPCR proteins**

Compelling evidence exists showing that GPCRs interact with specific non-GPCR proteins, and these interactions are very important in the regulation of the trafficking, maturation, cell surface expression, signaling, and/or desensitization of the receptors. These interacting proteins are called accessory or escort proteins (Achour et al., 2008; Roux and Cottrell, 2014).

MOL #104927

Formerly, it was believed that GPCRs were found mainly in the plasma membrane ready to be activated by their ligands. It is now known that most GPCRs accumulate as stock of functional receptors, or ready to finish maturation, in the ER or Golgi apparatus, and they traffic to the plasma membrane when needed (Doly and Marullo, 2015; Achour et al., 2008). Two types of proteins, the gatekeepers and the escort proteins, jointly regulate the push and pull from the ER or Golgi apparatus to the plasma membrane. The gatekeepers are ER or Golgi apparatus resident proteins that interact and retain GPCRs in the respective cellular compartment. The release of the GPCRs from the ER or Golgi apparatus occurs only after a competitive displacement of the GPCR/gatekeeper interaction by a GPCR/escort protein interaction (Doly and Marullo, 2015).

Recently, the existence of CRFR escort proteins has been described. The receptor activity-modifying protein 2 (RAMP2), one of the most studied escort proteins, functions as CRF<sub>1</sub>R escort protein, modifying cell surface expression and signaling of the receptor (Wootten et al., 2013). Using heterologous expression in cell cultures and ELISA assays to measure plasma membrane protein expression, Wootten et al. (2013) determined that RAMP2 increases the plasma membrane expression of CRF<sub>1</sub>R. Even more, measuring cAMP production, calcium mobilization and CRF<sub>1</sub>R/GTP $\gamma$ S binding, the authors showed that RAMP2 did not affect the ability of CRF<sub>1</sub>R to bind G<sub>s</sub> protein or of CRF<sub>1</sub>R agonists to stimulate cAMP production. Instead, it generated an increase in the ability of CRF<sub>1</sub>R to bind G<sub>i/o/v/z</sub>, G<sub>q/11</sub> and G<sub>12/13</sub> proteins and CRF<sub>1</sub>R was now able to mobilize intracellular calcium.

MOL #104927

Recently, it was shown that CRF-BP functions as a CRF<sub>2α</sub>R escort protein (Slater et al., 2016b). Using yeast two-hybrid assay and Co-IP in HEK293T cells extracts transfected with the corresponding proteins, it was shown that CRF-BP physically interacts with CRF<sub>2α</sub>R in an isoform specific manner, and using confocal microscopy, it was determined that CRF-BP increases CRF<sub>2α</sub>R plasma membrane levels (Slater et al., 2016b). Moreover, endogenous CRF-BP and CRF<sub>2α</sub>R co-localize in cultured mesencephalic neurons (Slater et al., 2016b) and co-exist in VTA synaptosomes (Slater et al., 2016a). Thus, this anatomical evidence indicates that CRF-BP and CRF<sub>2α</sub>R coexist in pre and postsynaptic elements in the VTA.

CRF<sub>2α</sub>R is expressed mainly in the ER (Fuenzalida et al., 2014; Slater et al., 2016b) where it is retained due to its described interaction with the ER resident protein calnexin (Schulz et al., 2010). Calnexin interacts with the CRF<sub>2α</sub>R pseudo-signal peptide (Schulz et al., 2010) and CRF-BP interacts with the N-terminal domain of CRF<sub>2α</sub>R (Slater et al., 2016b). Thus, it is tempting to suggest that a competitive displacement of the CRF<sub>2α</sub>R/Calnexin interaction by CRF-BP is necessary for the receptor to reach the plasma membrane.

Furthermore, there is evidence of a glutamate neurotransmission potentiation role of CRF-BP over CRF signaling through CRF<sub>2R</sub>, both pre- (Wang et al., 2005; 2007) and postsynaptically (Ungless et al., 2003) in the VTA after cocaine experience or stress. Further studies are necessary to determine whether the interaction between CRF<sub>2α</sub>R and CRF-BP is related to the requirement of the CRF interaction with CRF-BP to potentiate this addictive and stress related neuronal plasticity.

MOL #104927

In addition, a family of synaptic proteins known as membrane-associated guanylate kinases (MAGUKs) is important for the assembly and signaling of other proteins. MAGUK proteins contain PDZ domains, which can interact with a variety of proteins. The interaction of MAGUK proteins with multiple receptors is through the binding to the PDZ motifs present in the carboxyl terminal domain of the receptors (Kim and Sheng, 2004; Dunn and Ferguson, 2015).

CRF<sub>1</sub>R interacts with several MAGUK proteins: PSD95, PSD93, SAP102, SAP97, and MAGI2 (Dunn et al., 2013; Dunn et al., 2016; Walther et al., 2015). Dunn et al. (2013) showed the interaction between CRF<sub>1</sub>R and SAP97, an interaction dependent on the CRF<sub>1</sub>R PDZ domain that is not modified in the presence of agonists, such as CRF. Furthermore, SAP97 attenuates CRF-induced endocytosis of CRF<sub>1</sub>R, maintaining a higher level of CRF<sub>1</sub>R in the plasma membrane. On the other hand, the MAGUK protein PDZK1 interacts with CRF<sub>1</sub>R, increasing ERK1/2 signaling (Walther et al., 2015). PSD95 also interacts with CRF<sub>1</sub>R, and similar to SAP97, PSD95 attenuates ligand-induced endocytosis of CRF<sub>1</sub>R. However, PSD95 does not detectably alter CRF<sub>1</sub>R signaling (Dunn et al., 2016). CRF<sub>1</sub>R has a class I PDZ binding domain (STAV) in its C-terminal domain (Magalhaes et al., 2010). Bender et al. (2015), using yeast two-hybrid assays and Co-IP in HEK293 cells and neuronal cultures, as well as the modification of the STAV sequence of CRF<sub>1</sub>R, documented that it is the C-terminal domain of CRF<sub>1</sub>R that interacts with the PDZ domains of MAGUK proteins (Bender et al., 2015). Therefore, although CRF<sub>1</sub>R has a PDZ-binding domain that can interact with various MAGUK proteins, not all MAGUK proteins regulate CRF<sub>1</sub>R in the same way.



MOL #104927

After their agonists activate GPCRs, a process of desensitization occurs, which consists of preventing the GPCR/G-protein interaction followed by the endocytosis of the receptors. Usually, the desensitization process occurs due to the GPCRs interacting protein,  $\beta$ -arrestin. The phosphorylation of the receptor by the GPCR kinases (GRKs) is necessary for its interaction with  $\beta$ -arrestins and for targeting clathrin-coated pits for endocytosis (Kohout and Lefkowitz, 2003). Both CRF<sub>2</sub>R and CRF<sub>1</sub>R have a high degree of sequence conservation of consensus sites for phosphorylation by several protein kinases, which could modulate CRFRs function (Hauger et al., 2006). CRF<sub>1</sub>R is capable of recruiting  $\beta$ -arrestin 1 (Rasmussen et al., 2004) and  $\beta$ -arrestin 2 (Perry et al., 2005). Using confocal microscopy, Rasmussen et al. (2004) demonstrated that treatment with kinase inhibitors affects the recruitment of  $\beta$ -arrestin 1, but not CRF<sub>1</sub>R internalization. Thus,  $\beta$ -arrestin 1/CRF<sub>1</sub>R interaction is not necessary for CRF<sub>1</sub>R endocytosis in HEK293 cells. Similarly,  $\beta$ -arrestin 1 proteins do not internalize with CRF<sub>1</sub>R in primary cortical neurons (Holmes et al., 2006). Perry et al. (2005) showed that CRF<sub>1</sub>R is able to recruit  $\beta$ -arrestin 2 in HEK293 cells and in primary cortical neurons. Moreover,  $\beta$ -arrestin 2 internalizes with CRF<sub>1</sub>R in HEK293 cells, but not in cortical neurons. Using confocal microscopy, Hauger et al. (2013) demonstrated that CRF<sub>2 $\alpha$</sub> R can also recruit  $\beta$ -arrestin 2 in HEK293 cells in an agonist concentration-dependent manner, but they reported that  $\beta$ -arrestin 2 is not internalized with CRF<sub>2 $\alpha$</sub> R. Furthermore, Milan-Lobo et al. (2009) showed that both CRF<sub>2 $\beta$</sub> R and CRF<sub>1</sub>R homomers recruited  $\beta$ -arrestin upon agonist stimulation. However, they observed that CRF<sub>1</sub>R and not CRF<sub>2 $\beta$</sub> R was internalized. The available data of CRF-R interacting proteins have been obtained with heterologous overexpression of the interacting partners. Protein

MOL #104927

overexpression could lead to non-physiological protein/protein interactions. Due to the potential relevance of these interactions, they should be studied in physiological/physiopathological states.

## CONCLUSIONS

Increasing evidence shows that CRF receptors interact with themselves to form homomeric dimers (CRF<sub>1</sub>R and CRF<sub>2β</sub>R) and with other GPCRs to form heteromers (CRF<sub>1</sub>R and CRF<sub>2α</sub>R) (Fig. 1). At present, there is no evidence showing the interaction of CRF<sub>2β</sub>R with other GPCRs. In addition, CRF receptors interact with non-GPCR proteins that regulate their localization in the plasma membrane. CRF<sub>1</sub>R interacts with membrane-associated guanylate kinases, as well as with receptor activity-modifying protein 2 to increase its presence in the plasma membrane. CRF<sub>2α</sub>R, but not CRF<sub>2β</sub>R, interacts with CRF-BP, which facilitates its access to the plasma membrane. The interaction of these proteins has been observed only in heterologous overexpression assays. However, the anatomical evidence of their coexistence in specific neuronal phenotypes demands further *in vivo* studies to elucidate the potential contribution of the reviewed protein interactions in the stress response in health and disease. For instance, the reported interaction of CRF<sub>2α</sub>R with D<sub>1</sub>R and with CRF-BP may occur in the ventral tegmental area as well as in other brain regions involved in the interaction between stress and addiction. As proposed by Arzt and Holsboer (2006), selective signaling of CRF-R1 in different brain regions could be exploited to generate new pharmacological strategies to treat stress-related disorders. It is tempting to suggest that the differential signaling of CRF-R1 in different brain regions could be due to

MOL #104927

their interactions with other GPCRs or non-GPCR proteins. Thus, a better knowledge of such interactions and their functional consequences may open new pharmacological strategies to treat addictive behavior and stress-related disorders.

MOL #104927

## **AUTHORSHIP CONTRIBUTIONS**

Wrote or contributed to the writing of the manuscript: Slater, Yarur and Gysling.

MOL #104927

## REFERENCES

Achour L, Labbé-Jullié C, Scott MG, and Marullo S (2008) An escort for GPCRs: implications for regulation of receptor density at the cell surface. *Trends Pharmacol Sci* **29**:528-535.

Arzt E, Holsboer F (2006) CRF signaling: molecular specificity for drug targeting in the CNS. *Trends Pharmacol Sci* **27**:531-538.

Bale TL and Vale WW (2004) CRF and CRF receptors: role in stress responsivity and other behaviors. *Annu Rev Pharmacol Toxicol* **44**:525-557.

Bender J, Engholm M, Ederer MS, Breu J, Møller TC, Michalakis S, Rasko T, Wanker EE, Biel M, Martinez KL, Wurst W, and Deussing JM (2015) Corticotropin-releasing hormone receptor type 1 (CRHR1) clustering with MAGUKs Is mediated via Its C-terminal PDZ binding motif. *PLoS One*, 10(9):e0136768.

Blacktop JM, Seubert C, Baker DA, Ferda N, Lee G, Graf EN, and Mantsch JR (2011) Augmented cocaine seeking in response to stress or CRF delivered into the ventral tegmental area following long-access self-administration is mediated by CRF receptor type 1 but not CRF receptor type 2. *J Neurosci* **31**:11396-11403.

Bockaert J, Claeysen S, Bécamel C, Dumuis A, and Marin P (2006) Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling and roles in synaptic modulation. *Cell Tissue Res* **326**: 553–572.

Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF, and de Lecea L (2005) Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. *Proc Natl Acad Sci USA* **102**: 19168-19173.

Dautzenberg FM, Kilpatrick GJ, Hauger RL, and Moreau J (2001) Molecular biology of the CRH receptors-- in the mood. *Peptides* **5**:753-760.

Dautzenberg FM and Hauger RL (2002) The CRF peptide family and their receptors: yet more partners discovered. *Trends Pharmacol Sci* **2**:71-77.

Doly S and Marullo S (2015) Gatekeepers Controlling GPCR Export and Function. *Trends Pharmacol Sci* **10**:636-644.

Dunn HA, Walther C, Godin CM, Hall RA, and Ferguson SS (2013) Role of SAP97 protein in the regulation of corticotropin-releasing factor receptor 1 endocytosis and extracellular signal-regulated kinase 1/2 signaling. *J Biol Chem* **288**:15023–15034.

MOL #104927

Dunn HA and Ferguson SS (2015) PDZ Protein Regulation of G Protein-Coupled Receptor Trafficking and Signaling Pathways. *Mol Pharmacol* **88**:624-639.

Dunn HA, Chahal HS, Caetano FA, Holmes KD, Yuan GY, Parikh R, Heit B, and Ferguson SS (2016) PSD-95 regulates CRFR1 localization, trafficking and  $\beta$ -arrestin2 recruitment, *Cell Signal* **28**: 531-540.

Franco R, Casadó V, Cortés A, Mallol J, Ciruela F, Ferré S, Lluís C, and Canela EI. (2008). G-protein-coupled receptor heteromers: function and ligand pharmacology. *Br J Pharmacol* **153** Suppl 1: S90-98.

Fuenzalida J, Galaz P, Araya KA, Slater PG, Blanco EH, Campusano JM, Ciruela F, and Gysling K (2014) Dopamine D1 and corticotrophin-releasing hormone type-2 $\alpha$  receptors assemble into functionally interacting complexes in living cells. *Br J Pharmacol* **24**:5650-5664.

Gillies GE, Linton EA, and Lowry PJ (1982) Corticotropin releasing activity of the new CRF are potentiated several times by vasopressin. *Nature* **299**:355–357.

Grammatopoulos DK and Chrousos GP (2002) Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. *Trends Endocrinol Metab* **10**:436-444.

Guillon G, Gaillard RC, Kehrer P, Schoenenberg P, Muller AF, and Jard S (1987) Vasopressin and angiotensin induce inositol lipid break-down in rat adenohypophysial cells in primary culture. *Regul Pept* **18**:119 –129.

Gysling K (2012) Relevance of both type-1 and type-2 corticotropin releasing factor receptors in stress-induced relapse to cocaine seeking behaviour. *Biochem Pharmacol* **83**:1-5.

Hahn J, Hopf FW, Bonci A (2009) Chronic cocaine enhances corticotropin-releasing factor-dependent potentiation of excitatory transmission in ventral tegmental area dopamine neurons. *J Neurosci* **29**:6535-6544.

Hauger RL, Risbrough V, Brauns O, and Dautzenberg FM (2006) Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. *CNS Neurol Disord Drug Targets* **4**:453-479.

Hauger RL, Olivares-Reyes JA, Braun S, Hernandez-Aranda J, Hudson CC, Gutknecht E, Dautzenberg FM, and Oakley RH (2013) Desensitization of human CRF2(a) receptor signaling governed by agonist potency and  $\beta$ arrestin2 recruitment. *Regul Pept* **186**:62-76.

MOL #104927

Holmes KD, Babwah AV, Dale LB, Poulter MO, and Ferguson SS (2006) Differential regulation of corticotropin releasing factor 1alpha receptor endocytosis and trafficking by beta-arrestins and Rab GTPases. *J Neurochem* **4**:934-949.

Kehne JH (2007) The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. *CNS Neurol Disord Drug Targets* **6**:163-182.

Kim E and Sheng M (2004) PDZ domain proteins of synapses. *Nat Rev Neurosci* **5**:771-781.

Kohout TA and Lefkowitz RJ (2003) Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. *Mol Pharmacol* **63**:9-18.

Kostich WA, Chen A, Sperle K, and Largent BL (1998) Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. *Mol Endocrinol* **12**:1077-1085.

Kourrich S, Su T-P, Fujimoto M, and Bonci A (2012) The sigma-1 receptor: roles in neuronal plasticity and disease. *Trends Neurosci* **35**:762-771.

Kraetke O, Wiesner B, Eichhorst J, Furkert J, Bienert M, and Beyermann M (2005) Dimerization of corticotropin-releasing factor receptor type 1 is not coupled to ligand binding. *J Recept Signal Transduct Res* **25**:251-276.

McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. *Nature* **393**:333-339.

Liaw CW, Lovenberg TW, Barry G, Oltersdorf T, Grigoriadis DE, and de Souza EB (1996) Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. *Endocrinology* **137**:72-77.

Liebsch G, Landgraf R, Engelmann M, Lörcher P, and Holsboer F (1999) Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. *J Psychiatr Res* **33**:153-163.

Magalhaes AC, Holmes KD, Dale LB, Comps-Agrar L, Lee D, Yadav PN, Drysdale L, Poulter MO, Roth BL, Pin JP, Anisman H, Ferguson SS (2010) CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. *Nat Neurosci* **13**:622-629.

Magalhaes AC, Dunn H, Ferguson SS (2012) Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. *Br J Pharmacol* **165**:1717-1736.

MOL #104927

Milan-Lobo L, Gsandtner I, Gaubitzer E, Rünzler D, Buchmayer F, Köhler G, Bonci A, Freissmuth M, Sitte HH (2009) Subtype-specific differences in corticotropin-releasing factor receptor complexes detected by fluorescence spectroscopy. *Mol Pharmacol* **76**:1196-1210.

Müller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P, Kormann MS, Droste SK, Kühn R, Reul JM, Holsboer F, Wurst W (2003) Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. *Nat Neurosci* **6**:1100-1107.

Murat B, Devost D, Andrés M, Mion J, Boulay V, Corbani M, Zingg HH, and Guillon G (2012) V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH. *Mol Endocrinol* **26**: 502-520.

Navarro G, Quiroz C, Moreno-Delgado D, Sierakowiak A, McDowell K, Moreno E, Rea W, Cai NS, Aguinaga D, Howell LA, Hausch F, Cortés A, Mallol J, Casadó V, Lluís C, Canela EI, Ferré S, and McCormick PJ (2015) Orexin-corticotropin-releasing factor receptor heteromers in the ventral tegmental area as targets for cocaine. *J Neurosci* **35**: 6639–6653.

Neve KA, Seamans JK, and Trantham-Davidson H (2004) Dopamine receptor signaling. *J Recept Signal Transduct Res* **24**:165-205.

O'Dowd BF, Ji X, Alijaniam M, Rajaram RD, Kong MM, Rashid A, Nguyen T, and George SR (2005) Dopamine receptor oligomerization visualized in living cells. *J Biol Chem* **280**:37225-37235.

Orozco-Cabal L, Liu J, Pollandt S, Schmidt K, Shinnick-Gallagher P, and Gallagher JP (2008) Dopamine and corticotropin-releasing factor synergistically alter basolateral amygdala-to-medial prefrontal cortex synaptic transmission: functional switch after chronic cocaine administration. *J Neurosci* **28**:529-542.

Pal K, Swaminathan K, Xu HE, and Pioszak AA (2010) Structural basis for hormone recognition by the Human CRFR2{alpha} G protein-coupled receptor. *J Biol Chem* **285**:40351-40361.

Perry SJ, Junger S, Kohout TA, Hoare SR, Struthers RS, Grigoriadis DE, and Maki RA (2005) Distinct conformations of the corticotropin releasing factor type 1 receptor adopted following agonist and antagonist binding are differentially regulated. *J Biol Chem* **280**:11560-11568.

Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA, Lohse MJ, Milligan G, Palczewski K, Parmentier M, and Spedding M (2007) International Union of Basic and



MOL #104927

Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. *Pharmacol Rev* **59**: 5–13.

Rasmussen TN, Novak I, and Nielsen SM (2004) Internalization of the human CRF receptor 1 is independent of classical phosphorylation sites and of beta-arrestin 1 recruitment. *Eur J Biochem* **271**:4366-4374.

Reul JM, Holsboer F (2002) Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. *Curr Opin Pharmacol* **2**:23-33.

Rozenfeld R, Devi LA (2010) Receptor heteromerization and drug discovery. *Trends Pharmacol Sci* **31**:124-130.

Roux BT and Cottrell GS (2014) G protein-coupled receptors: what a difference a 'partner' makes. *Int J Mol Sci* **15**:1112-1142.

Rutz C, Renner A, Alken M, Schulz K, Beyermann M, Wiesner B, Rosenthal W, and Schülein R (2006) The corticotropin-releasing factor receptor type 2a contains an N-terminal pseudo signal peptide. *J Biol Chem* **281**:24910-24921.

Schulz K, Rutz C, Westendorf C, Ridelis I, Vogelbein S, Furkert J, Schmidt A, Wiesner B, and Schülein R (2010) The pseudo signal peptide of the corticotropin-releasing factor receptor type 2a decreases receptor expression and prevents Gi-mediated inhibition of adenylyl cyclase activity. *J Biol Chem* **285**:32878-32887.

Shaham Y, Erb S, Leung S, Buczek Y, and Stewart J (1998) CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. *Psychopharmacology* **137**: 184-190.

Slater PG, Noches V, and Gysling K (2016a) Corticotropin-releasing factor type-2 receptor and corticotropin-releasing factor-binding protein coexist in rat ventral tegmental area nerve terminals originated in the lateral hypothalamic area. *Eur J Neurosci* **43**:220-229.

Slater PG, Cerda CA, Pereira LA, Andrés ME, and Gysling K (2016b) CRF binding protein facilitates the presence of CRF type 2 $\alpha$  receptor on the cell surface. *Proc Natl Acad Sci USA* **113**:4075-4080.

Sotomayor-Zárate R, Abarca J, Araya KA, Renard GM, Andrés ME, Gysling K (2015) Exposure to repeated immobilization stress inhibits cocaine-induced increase in dopamine extracellular levels in the rat ventral tegmental area. *Pharmacol Res* **101**:116-123.

Szafran K, Faron-Górecka A, Kolasa M, Kuśmider M, Solich J, Zurawek D, and Dziedzicka-Wasylewska M (2013) Potential role of G protein-coupled receptor (GPCR)

MOL #104927

heterodimerization in neuropsychiatric disorders: a focus on depression. *Pharmacol Rep* **65**:1498-1505.

Tan H, Zhong P, and Yan Z (2004) Corticotropin-releasing factor and acute stress prolongs serotonergic regulation of GABA transmission in prefrontal cortical pyramidal neurons. *J Neurosci* **24**: 5000–5008.

Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu T, Mori T, and Tsujimoto G (2004) The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. *J Clin Invest* **113**: 302-329.

Teichmann A, Rutz C, Kreuchwig A, Krause G, Wiesner B, and Schülein R (2012) The Pseudo signal peptide of the corticotropin-releasing factor receptor type 2A prevents receptor oligomerization. *J Biol Chem* **287**:27265-27274.

Teichmann A, Gibert A, Lampe A, Grzesik P, Rutz C, Furkert J, Schmoranzler J, Krause G, Wiesner B, and Schülein R (2014) The specific monomer/dimer equilibrium of the corticotropin-releasing factor receptor type 1 is established in the endoplasmic reticulum. *J Biol Chem* **289**: 24250-24262.

Terrillon S and Bouvier M (2004) Roles of G-protein-coupled receptor dimerization. *EMBO Rep* **5**:30-34.

Ungless MA, Singh V, Crowder TL, Yaka R, Ron D, and Bonci A (2003) Corticotropin-releasing factor requires CRF binding protein to potentiate NMDA receptors via CRF receptor 2 in dopamine neurons. *Neuron* **39**: 401-407.

Valdenaire O, Giller T, Breu V, Gottowik J, and Kilpatrick G (1997) A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor. *Biochim Biophys Acta* **1352**:129-132.

Walther C, Caetano FA, Dunn HA, and Ferguson SS (2015) PDZK1/NHERF3 differentially regulates corticotropin-releasing factor receptor 1 and serotonin 2 A receptor signaling and endocytosis. *Cell Signal* **27**: 519–531.

Wang B, Shaham Y, Zitzman D, Azari S, Wise RA, You ZB (2005) Cocaine experience establishes control of midbrain glutamate and dopamine by corticotropin-releasing factor: a role in stress-induced relapse to drug seeking. *J Neurosci* **25**:5389-5396.

Wang B, You ZB, Rice KC, Wise RA (2007) Stress-induced relapse to cocaine seeking: roles for the CRF(2) receptor and CRF-binding protein in the ventral tegmental area of the rat. *Psychopharmacology (Berl)* **193**:283-294.

MOL #104927

Wang B, You ZB, and Wise RA (2009) Reinstatement of cocaine seeking by hypocretin (orexin) in the ventral tegmental area: independence from the local corticotropin-releasing factor network. *Biol Psychiatry* **65**: 857-862.

Waselus M, Nazzaro C, Valentino RJ, and Van Bockstaele EJ (2009) Stress-induced redistribution of corticotropin-releasing factor receptor subtypes in the dorsal raphe nucleus. *Biol Psychiatry* **66**:76-83.

White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH, Barnes AA, Emson P, Foord SM, and Marshall FH (1998) Heterodimerization is required for the formation of a functional GABAB receptor. *Nature* **396**: 679-682.

Williams CL, Buchta WC, Riegel AC (2014) CRF-R2 and the heterosynaptic regulation of VTA glutamate during reinstatement of cocaine seeking. *J Neurosci* **34**:10402-10414.

Wood SK, Zhang XY, Reyes BA, Lee CS, Van Bockstaele EJ, and Valentino RJ (2013) Cellular adaptations of dorsal raphe serotonin neurons associated with the development of active coping in response to social stress. *Biol Psychiatry* **73**:1087-1094.

Wootten D, Lindmark H, Kadmiel M, Willcockson H, Caron KM, Barwell J, Drmota T, and Poyner DR (2013) Receptor activity modifying proteins (RAMPs) interact with the VPAC2 receptor and CRF1 receptors and modulate their function. *Br J Pharmacol* **168**:822-834.

Young SF, Griffante C, and Aguilera G (2007) Dimerization between vasopressin V1b and corticotropin releasing hormone type 1 receptors. *Cell Mol Neurobiol* **27**: 439-461.

Zorrilla EP, Logrip ML, Koob GF (2014) Corticotropin releasing factor: a key role in the neurobiology of addiction. *Front Neuroendocrinol* **35**:234-244.

MOL #104927

### **Footnote**


This work was supported by FONDECYT grant N° 1150244 and by CONICYT PhD fellowships to PGS and HEY. PGS and HEY contributed equally.

MOL #104927


### Figure legend

**Figure 1.** Schematic representation of CRF<sub>1</sub>R and CRF<sub>2α</sub>R highlighting protein interactions of both receptors. The presence of the non-cleavable signal peptide in the N-terminal of CRF<sub>2α</sub>R determines significant differences in the repertoire of interacting proteins with each receptor. The differences in the amino acid sequence in the C-terminal of both receptors determine the interaction of CRF<sub>1</sub>R, but not CRF<sub>2α</sub>R, with MAGUK proteins and with 5-HT<sub>2</sub>R.

# CRF<sub>1</sub>R



# CRF<sub>α</sub>R



Downloaded from [aspejournal.org](http://aspejournal.org) at ASPET Journals on April 19, 2024